Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World May 4, 2011 Andrew Turley	Teva sidelines Valeant with $6.8bn Cephalon bid US drugmaker Cephalon has agreed to a $6.8 billion ( 4.1 billion) takeover bid from Israeli generics manufacturer Teva, which has beaten into second place Canadian pharma company Valeant.
The Motley Fool September 20, 2007 Brian Orelli	Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note.
The Motley Fool August 27, 2008 Brian Orelli	Teva Tells It Like It Is For Teva Pharmaceuticals, the details only confirmed the great initial report of the clinical trial success for its Parkinson's disease treatment Azilect.
Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
The Motley Fool July 18, 2008 Rich Duprey	More Group Therapy From Generics The Teva deal for Barr shows consolidation is still underway in the industry.
The Motley Fool July 8, 2008 Brian Orelli	Not Teva's Forte Teva Pharmaceutical's Copaxone for multiple sclerosis fails to show a benefit at double strength. Investors take note.
The Motley Fool April 13, 2010 Brian Orelli	Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development.
The Motley Fool June 30, 2005 Brian Gorman	Teva's Non-Generic Side The drug company is working hard to cement its position in the market for multiple sclerosis meds. Investors, take note.
BusinessWeek November 3, 2003 Diane Brady	Biotech: Teva's Next Triumph? The Israeli maker of generics wants a piece of the fast-growing bio-drug market.
The Motley Fool November 8, 2006 Brian Lawler	Teva Is Rolling in Cash Again Investors, the bottom line is that with 13 proprietary drugs in phase 2 trials or later for some very large indications, plus 144 applications to sell generic versions of branded drugs waiting at the FDA, Teva's near-term future is strong.
The Motley Fool November 26, 2008 Brian Orelli	Watson Gets Some Hand-Me-Downs Much like discount stores, generic-drug makers are in a cutthroat low-margin business, where "larger" almost always means "better."
The Motley Fool July 25, 2005 Stephen D. Simpson	Teva Tries to Buy Back the Top Spot $7.4 billion later, Teva Pharmaceuticals is poised to become the largest generics company in the world once again. Investors, take note.
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool August 1, 2005 Stephen D. Simpson	Teva: Built to Last? Israeli generics giant Teva Pharmaceuticals is a high-quality company trading at a level that should still provide patient investors with solid long-term performance.
The Motley Fool September 22, 2009 Robert Steyer	Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge.
The Motley Fool February 15, 2005 Stephen D. Simpson	Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
The Motley Fool March 31, 2008 Rich Duprey	Teva's Tough Pill to Swallow Eisai wins a preliminary injunction against Teva's generic Alzheimer's treatment.
The Motley Fool May 5, 2010 Brian Orelli	Teva's Double-Edged Sword Nice quarter, but where will future growth come from?
Chemistry World October 14, 2013 Phillip Broadwith	5000 jobs to be cut at Teva Israeli generics heavyweight Teva is accelerating its previously announced costcutting drive.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool November 5, 2004 Roger Nusbaum	The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy.
The Motley Fool May 5, 2009 Brian Orelli	Generic Growth, Acquisition Style Sales at Teva Pharmaceuticals were up 22% year over year, but don't bust out the champagne just yet.
The Motley Fool April 25, 2011 Sean Williams	Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing.
The Motley Fool May 3, 2011 Brian Orelli	Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.
The Motley Fool May 7, 2008 Brian Orelli	Teva's on a Tear The generic-drug maker can't be stopped.
The Motley Fool February 17, 2010 Brian Orelli	This Is Not Your Generic Cash Production Teva's generating cash and knows how to use it.
The Motley Fool June 30, 2005 Brian Gorman	The Co-Pay Effect Higher co-payments look like the wave of the future, and investors should expect the trend to boost major generic players like Teva Pharmaceutical, Mylan Laboratories, and Novartis.
The Motley Fool July 1, 2008 Brian Orelli	As the FDA Generics Office Turns The FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal.
The Motley Fool February 13, 2008 Brian Orelli	Teva Tears It Up After a stellar 2006 because of exclusive launches of some big-time generics, it seemed like Teva Pharmaceuticals would have a heck of a time keeping the pace up in 2007. Apparently, that fear was unwarranted.
The Motley Fool January 23, 2008 Brian Orelli	Teva Buys In to Biologics Teva Pharmaceutical announces that it was acquiring privately held CoGenesys, for $400 million in cash.
The Motley Fool May 12, 2011 Brian Orelli	Teva's Mixed Bag Diversification sure helps.
BusinessWeek July 29, 2009 Arlene Weintraub	Teva Fights for Biotech Generics Teva's Debra Barrett is lobbying hard to shorten the protection period for biotech drugs and get generic versions to market more quickly
The Motley Fool August 6, 2011 Sean Williams	10 Large Caps to Rule Them All There's nothing generic about this company. For the inaugural large-cap pick, I think we should revisit pharma's most impervious pipeline, Teva Pharmaceuticals.
The Motley Fool October 13, 2009 Dave Mock	A Big Upgrade for Teva Pharmaceutical This bullish call comes from more than just one analyst.
Chemistry World May 21, 2009 Matt Wilkinson	Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets.
Pharmaceutical Executive October 1, 2006 Joanna Breitstein	"I Pray for the Welfare of Your Company..." Big Pharma's drugs fill Teva Pharmaceutical's pipeline. CEO Israel Makov says he's not the enemy. To prove it, he offers lessons in survival.
The Motley Fool November 3, 2010 Brian Orelli	Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits.
The Motley Fool February 28, 2006 Stephen D. Simpson	Still Waiting for Teva to Stumble This leading Israeli generics firm hasn't seen a stock pullback of any consequence since mid- to late 2004. And while fourth-quarter results weren't fabulous, they were good enough given the circumstances
The Motley Fool August 8, 2006 Stephen D. Simpson	Nothing Generic About Teva's Performance Once again, buying this this Israeli generics giant on dips returns a tidy profit.
The Motley Fool May 10, 2006 Stephen D. Simpson	Time to Make Room for Teva? This might be a rare chance to pick up a dominant company at an attractive price. Investors, take note.
The Motley Fool August 28, 2007 Brian Orelli	Teva Gets a Two-For Even for a maker of generic drugs, getting two FDA drug approvals in as many business days is a feat not often seen. Teva Pharmaceuticals managed to do it, though. Investors, take note.
The Motley Fool November 3, 2009 Brian Orelli	Nice Quarter, Teva. What Will You Buy Next? Branded or generic, it's always a tough call.
The Motley Fool April 11, 2008 Brian Orelli	Teva Tugs at Both Ends of the MS String Teva tries to get multiple sclerosis patients to switch to its drug.
The Motley Fool June 26, 2006 Stephen D. Simpson	Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note.
The Motley Fool June 28, 2011 Eric Bleeker	Where Is Teva Pharmaceuticals Finding Growth? Teva should see its sales continue to climb, especially in already booming international markets.
The Motley Fool June 6, 2005 Stephen D. Simpson	"Bad News" for Teva? Yawn... Be ready to act when the market overreacts. For those investors who think that Teva Pharmaceutical will maintain its top-dog status in the generics world, this is just a blip on the scope and/or the opportunity to build a position.
The Motley Fool July 28, 2009 Brian Orelli	All Growth, All the Time This generic-drug maker is no value play.
The Motley Fool September 25, 2008 Brian Orelli	Teva Heads to Japan It's conquering the world, slowly but surely. But is it still a value play?
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool December 26, 2007 Brian Orelli	Teva's Heartburning Battle Teva launches its generic version of Wyeth's and Altana's heartburn medication, Protonix; those companies attempt to get a preliminary injunction. There are high stakes on both sides of the dispute.